artículo
Small interfering RNA for cancer treatment: overcoming hurdles in delivery
Fecha
2020Registro en:
Nitin Bharat Charbe, Nikhil D. Amnerkar, Murtaza M. Tambuwala, Hamid A. Bakshi, Alaa A.A. Aljabali, Saurabh C. Khadse, Rajendran Satheeshkumar, Saurabh Satija, Meenu Metha, Dinesh Kumar Chellappan, Garima Shrivastava, Gaurav Gupta, Poonam Negi, Kamal Dua, Flavia C. Zacconi. Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Science. 2020;(10005):1-1.
10.1016/j.apsb.2020.10.005
2211-3835
WOS:000595499500005
Autor
Zacconi, Flavia C. M.
Aljabali, Alaa A.A.
Chellappan, D.K.
Shrivastava, Garima
Gupta, Gaurav
Bakshi, Hamid A.
Dua, Kamal
Metha, Meenu
Tambuwala, Murtaza M.
Amnerkar, Nikhil D.
Charbe, Nitin Bharat
Negi, Poonam
Satheeshkumar, Rajendran
Khadse, Saurabh C.
Satija, Saurabh
Institución
Resumen
In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.